Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Study participants with non-cystic fibrosis bronchiectasis will be given Trikafta for four
weeks. The researchers will monitor clinical endpoints, quality of life, and weight.
Additionally, cutaneous punch biopsy material will be collected from each participant to test
cellular response to Trikafta.